WHO ICTRP trial
Vivo Bioequivalence study
IRCT20200105046010N117 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200105046010N117 |
|---|---|
| Public title | Vivo Bioequivalence study |
| Scientific title | In Vivo Bioequivalence study of Sumatriptan/Naproxen Pars-Gita Darou (MigrExtra® 500/85 mg ) with brand drugs (TREXIMET®500/85 mg) Currax Pharmaceuticals LLC in Iranian healthy volunteers. |
| Primary sponsor | ???? ???? ???? ???? |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | In this study the bioequivalence of test and brand of MigrExtra® will be evaluated.. |
| Interventions | Control group: Intervention group: Single-dose (TREXIMET® Tabs. 85/500 mg. Currax Pharma, UK ) as reference product.. |
| Registration date | Aug 26, 2024 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: